Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03795389 · ClinicalTrials.gov registry record · Phase 1
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
A Phase 1 study of Diabetes and Chronic Kidney Disease, sponsored by DiaMedica Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 3
- Study locations
NCT03795389 is a Phase 1 study of Diabetes and Chronic Kidney Disease that has completed, run by DiaMedica Therapeutics. The registered enrollment target is 33 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT03795389, a Phase 1 study of Diabetes and Chronic Kidney Disease, has completed, sponsored by DiaMedica Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 3
- Study locations
Study Summary
An open-label, phase IB, multi-center study evaluating DM199 in subjects with Type 1 Diabetes or Type 2 Diabetes and Stage 3 or 4 Chronic Kidney Disease. The primary objectives of this study are to evaluate safety, tolerability, and PK profile of DM199 in these subjects.
Conditions Studied
Interventions
- DRUG DM199
Study Locations (3)
Florida
- Clinical Pharmacology of Miami - Hialeah
- Orlando Clinical Research Center Inc - Orlando
Minnesota
- Prism Research - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-02-12 |
| Est. Completion | 2019-07-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03795389
The ClinicalTrials.gov registry entry for NCT03795389 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is DiaMedica Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which DM199 is the first listed.
NCT03795389 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03795389 about?
NCT03795389 is a clinical study titled "Study to Assess PK, Safety and Tolerability in Patients With DM and CKD". An open-label, phase IB, multi-center study evaluating DM199 in subjects with Type 1 Diabetes or Type 2 Diabetes and Stage 3 or 4 Chronic Kidney Disease. The primary objectives of this study are to evaluate safety, tolerability, and PK profile of DM199 in these subjects.
What is the current status of trial NCT03795389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2019-02-12. Estimated completion is 2019-07-21.
What conditions does trial NCT03795389 study?
This clinical trial studies the following conditions: Diabetes, Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe).
What interventions are being tested in trial NCT03795389?
The interventions under investigation include: DM199 (DRUG).
Who is sponsoring clinical trial NCT03795389?
This trial is sponsored by DiaMedica Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03795389 being conducted?
This trial has 3 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mitigating the Pro-inflammatory Phenotype of Obesity
RECRUITING · Phase 1
-
Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
RECRUITING · Phase 1
-
Insulin Balanced Infusion System
ACTIVE NOT RECRUITING · Phase 1
-
Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption
COMPLETED · Phase 1
-
Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
COMPLETED · Phase 1
-
Family Management of Childhood Diabetes Study
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.